We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS Clears Federal Probe Surrounding Generic Plavix Deal
BMS Clears Federal Probe Surrounding Generic Plavix Deal
March 2, 2007
One of the federal investigations into a reverse-payment deal involving generic Plavix found no violations of federal securities laws on the part of Bristol-Myers Squibb (BMS), the company said.